Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00
MarketBeatChardan Capital lifted their price target on Avidity Biosciences from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday.
Chardan Capital lifted their price target on Avidity Biosciences from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday.
